The primary objective of this proposal is to develop and commercialize a safe and more effective therapy for the treatment of Crohn's Disease, an inflammatory bowel disease. Crohn's Disease is a chronic inflammatory disorder of the gastrointestinal tract that affects some 500,000 patients in the US. Selexys Pharmaceuticals is developing a fully human anti-PSGL-1 antibody drug directed against P-selectin glycoprotein ligand-1 (PSGL-1), a dimeric mucin on circulating leukocytes that binds selectins and chemokines, for the treatment of Crohn's Disease. PSGL-1 mediates the first step in the recruitment of leukocytes to sites of inflammation by binding to selectins, cell adhesion molecules that are upregulated in Crohn's Disease patients. PSGL-1 also binds chemokines that amplify the inflammatory response through chemotaxis of inflammatory cells to endothelial cells that line the gut. In preclinical studies in animal models of Crohn's Disease, anti-PSGL-1 antibodies have been shown to block recruitment of leukocytes resulting in a profound therapeutic effect. Thus anti-PSGL-1 antibodies represent a novel new potential therapeutic approach in the treatment of Crohn's Disease. In Phase 1 of this Fast Track Proposal, Selexys is proposing to conduct primate safety and toxicity studies in cynomolgus monkey with a human anti-PSGL-1 IgG2 antibody that has been engineered to lack effector function and complement binding. Pharmacokinetic (PK), pharmacodynamic (PD) and immunogenicity bioassays in support of this proposal are currently being developed by Selexys. Manufacture of drug substance to support the proposed preclinical studies and clinical trials is underway at Cytovance Biologics in Oklahoma City. Selexys is proposing to conduct a PK pilot dose ranging study in cynomolgus monkey (Macaca fascicularis) to assess safety and PK of the anti-PSGL-1 antibody. The pilot study will guide dosing plans to conduct an IND enabling 4-week IV repeat dose toxicity study in cynomolgus monkey. In Phase 2 of this application Selexys proposes to conduct a Phase I safety study in healthy volunteers leading to a Phase IIa safety and efficacy trial in Crohn's Disease patients. The primary goal of the proposed study is to characterize the antibody prior to commencing a Phase IIb six months chronic dosing trial. The overarching goal of the program is to develop and commercialize a humanized antibody to PSGL- 1 to treat Crohn's Disease patients. In doing so Selexys will address an inflammatory bowel disease with major unmet medical needs with a therapy that may be safer than current approved biologic therapies and that has the potential to sustain remission and/or ameliorate the devastating effects of this disease. , ,
Public Health Relevance: This proposal supports development of a fully human antibody to PSGL-1 to treat Crohn's Disease patients. Crohn's Disease is an inflammatory bowel disease that affects 500,000 persons in the U.S. The drug being developed addresses a major unmet medical need for a therapy that can maintain remission and/or ameliorate the devastating effects of this disease.
Thesaurus Terms: Acute;Address;Adhesion Molecule;Adhesions;Adverse Effects;Affect;Affinity;Alimentary Canal;Animal Model;Animal Models And Related Studies;Antibodies;Assay;Binding;Binding (Molecular Function);Bioassay;Biologic Assays;Biologic Therapy;Biological Assay;Biological Response Modifier Therapy;Biological Therapy;Blood Leukocyte;Body Tissues;C-Reactive Protein;Cd162 Antigen;Cell Adhesion Molecules;Cell Line;Cell Lines, Strains;Cellline;Cells;Chemotaxis;Chronic;Cities;Clinical;Clinical Research;Clinical Study;Clinical Trials;Clinical Trials, Phase I;Clinical Trials, Phase Ii;Clinical Trials, Unspecified;Complement;Complement Proteins;Contracting Opportunities;Contracts;Crab-Eating Macaque;Crohn's Disease;Crohn's Disorder;Cytokines, Chemotactic;Data;Development;Digestive Tract;Disease;Disease Remission;Disorder;Dose;Drug Kinetics;Drugs;Early-Stage Clinical Trials;Endothelial Cells;Engineering;Engineerings;Enteritis, Granulomatous;Gi Tract;Gastrointestinal Tract;Gastrointestinal Tract Structure;Goals;Grant;Half-Life;Half-Lifes;Homologous Chemotactic Cytokines;Hu-Mabs;Human;Human Volunteers;Human, General;Inflm;Iv Drip;Igg2;Inflammation;Inflammatory;Inflammatory Bowel Diseases;Inflammatory Bowel Disorder;Inflammatory Intestinal Disease;Inflammatory Intestinal Disorder;Inflammatory Response;Intercrines;Intestinal;Intestines;Intravenous Drip;Intravenous Infusion;Leukocyte Rolling;Leukocytes;Mab Therapeutics;Macaca;Macaca Fascicularis;Macaque;Mammals, Primates;Man (Taxonomy);Man, Modern;Marrow Leukocyte;Mediating;Medical;Medication;Molecular Interaction;Monkey, Crab-Eating;Monkey, Cynomolgus;Mucins;Mucus Glycoprotein;Oklahoma;P-Selectin Glycoprotein Ligand-1;P-Selectin Ligand Protein;Psgl-1;Patients;Persons;Pharmaceutic Preparations;Pharmaceutical Agent;Pharmaceutical Preparations;Pharmaceuticals;Pharmacodynamics;Pharmacokinetics;Pharmacologic Substance;Pharmacological Substance;Pharmacology;Phase;Phase 1 Clinical Trials;Phase 2 Clinical Trials;Phase I Clinical Trials;Phase I Study;Phase Ii Clinical Trials;Pilot Projects;Prevention;Primates;Programs (Pt);Programs [publication Type];Property;Property, Loinc Axis 2;Proteins, Specific Or Class, C-Reactive;Qol;Quality Of Life;Rmsn;Regimen;Remission;Reticuloendothelial System, Leukocytes;Sis Cytokines;Safety;Selectins;Site;Specificity;Testing;Therapeutic;Therapeutic Effect;Therapeutic Monoclonal Antibodies;Therapeutic Antibodies;Tissues;Toxic Effect;Toxicities;Toxicokinetics;Toxicology;Treatment Side Effects;White Blood Cells;White Cell;Work;Alimentary Tract;Base;Biotherapeutics;Biotherapy;Bowel;Cell Adhesion Protein;Chemoattractant Cytokine;Chemokine;Clinical Investigation;Cross Reactivity;Cultured Cell Line;Design;Designing;Digestive Canal;Disease/Disorder;Drip Infusion;Drug/Agent;Effective Therapy;Efficacy Trial;Eleocolitis;Granulomatous Enterocolitis;Healthy Volunteer;Human Monoclonal Antibodies;Humanized Antibody;Immunogenic;Immunogenicity;Improved;Indexing;Inflammatory Marker;Inhibitor;Inhibitor/Antagonist;Innovate;Innovation;Innovative;Intravenous Administration;Model Organism;Novel;Phase 1 Study;Phase 1 Trial;Phase 2 Study;Phase 2 Trial;Phase I Trial;Phase Ii Trial;Pilot Study;Preclinical Study;Prevent;Preventing;Programs;Protocol, Phase I;Protocol, Phase Ii;Public Health Relevance;Randomized Placebo Controlled Study;Randomized Placebo Controlled Trial;Regional Enteritis;Safety Study;Side Effect;Study, Phase Ii;Therapy Adverse Effect;Treatment Adverse Effect;Vein Infusion;Volunteer;White Blood Cell;White Blood Corpuscle
